This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsimberidou, A. M. Articles by Keating, M. J. Search for Related Content PubMed PubMed Citation Articles by Tsimberidou, A. M. Articles by Keating, M. J. Social Bookmarking                            What's this?

Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2,126 Patients: 20 Years of Experience at The University of Texas M.D. Anderson Cancer Center

Apostolia M. Tsimberidou, Sijin Wen, Susan O'Brien, Peter McLaughlin, William G. Wierda, Alessandra Ferrajoli, Stefan Faderl, John Manning, Susan Lerner, Chinh V. Mai, Alma M. Rodriguez, Mark Hess, Kim-Anh Do, Emil J. Freireich, Hagop M. Kantarjian, L. Jeffrey Medeiros, Michael J. Keating

From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Apostolia M. Tsimberidou, MD, PhD, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030; e-mail: atsimber{at}mdanderson.org

Purpose Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are currently considered the same entity, but controversy remains over whether CLL and SLL should be treated similarly. We assessed whether characteristics of patients with CLL and SLL differ in ways other than the absolute lymphocyte count (ALC) and evaluated treatment outcomes and prognostic factors.

Methods We searched the electronic database for patients with CLL or SLL who presented to The University of Texas M.D. Anderson Cancer Center (Houston, TX) between 1985 and 2005. We reviewed patient records to determine presenting characteristics, treatment, and clinical outcomes. Cox models using training and validation sets of patients and resampling methods were used to develop a model predicting survival.

Results Among 2,126 consecutive CLL/SLL patients, 312 (15%) had ALC less than 5 x 10⁹/L. Patients with ALC less than 5 x 10⁹/L had lower rates of cytogenetic abnormalities (P = .0002) and higher rates of CD38-positive results (P = .0002) and had mutated immunoglobulin heavy-chain variable region gene status (P = .034). Rates of response, survival, and failure-free survival (FFS) were not different among ALC groups. Regimens that included rituximab and a nucleoside analog were associated with superior rates of response and FFS compared with other therapies, irrespective of ALC. Deletion 17p or 6q with or without other cytogenetic abnormalities, age at least 60 years, β₂-microglobulin at least 2 mg/L, albumin less than 3.5 g/dL, and creatinine at least 1.6 mg/dL were each found to independently predict shorter survival and formed the basis of a scoring system.

Conclusion Patients with CLL or SLL can be treated similarly. A new prognostic score is proposed.

Supported in part by the Wolf Creek Charitable Foundation and the American Society of Clinical Oncology Development Award (A.M.T.).

Presented in part at the 9th International Conference on Malignant Lymphoma, June 9-11, 2005, Lugano, Switzerland; at the 47th Annual Meeting of the American Society of Hematology, December 10-13, 2005, Atlanta, GA; and at the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, FL.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. F. Eichhorst, R. Busch, S. Stilgenbauer, M. Stauch, M. A. Bergmann, M. Ritgen, N. Kranzhofer, R. Rohrberg, U. Soling, O. Burkhard, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Blood, October 15, 2009; 114(16): 3382 - 3391. [Abstract] [Full Text] [PDF]

				G. S. Nowakowski, T. D. Shanafelt, S. Schwager, and N. E. Kay Reply to R.S. Go J. Clin. Oncol., August 1, 2009; 27(22): e45 - e45. [Full Text] [PDF]

				A.-M. Tsimberidou, S. Wen, P. McLaughlin, S. O'Brien, W. G. Wierda, S. Lerner, S. Strom, E. J Freireich, L. J. Medeiros, H. M. Kantarjian, et al. Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma J. Clin. Oncol., February 20, 2009; 27(6): 904 - 910. [Abstract] [Full Text] [PDF]

				A. M. Tsimberidou, W. G. Wierda, W. Plunkett, R. Kurzrock, S. O'Brien, S. Wen, A. Ferrajoli, F. Ravandi-Kashani, G. Garcia-Manero, Z. Estrov, et al. Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia J. Clin. Oncol., January 10, 2008; 26(2): 196 - 203. [Abstract] [Full Text] [PDF]